We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App





Horiba Presents Comprehensive Range of Hematology, Hemostasis and Clinical Chemistry Analyzers at MEDLAB Middle East

By LabMedica International staff writers
Posted on 24 Jan 2022
Print article
Image: Horiba at MEDLAB Middle East 2022 (Photo courtesy of Horiba Medical)
Image: Horiba at MEDLAB Middle East 2022 (Photo courtesy of Horiba Medical)

Horiba Medical (Kyoto, Japan) presented its comprehensive hematology, hemostasis and clinical chemistry analyzer ranges, as well as its HELO Solution that meets all laboratory configuration needs at MEDLAB Middle East 2022.

At the 2022 edition of MEDLAB Middle East, Horiba displayed its Yumizen G Range of five hemostasis analyzers and a comprehensive reagents menu from routine to specialized tests. Also on display was Horiba’s new compact hematology system the Yumizen H550 that provides full walk-away capability to small-mid size laboratories. The Yumizen H550 is a compact hematology system with integrated sample rack auto loading that is designed to provide rapid testing and full hematology diagnosis. It provides the operator with a full walk-away capacity of 40 tubes with continuous loading. Based on proven and innovative technologies, it answers the need for a robust analyzer and requires no user maintenance. Horiba also displayed the Yumizen H2500, its new generation automated hematology analyzer that answers customers expectations of solid and reliable diagnostic technology as well as rapid and consistent results.

The focus at Horiba’s demonstrations at the event was on the company’s global hematology solution, the HELO Solution (HORIBA Evolutive Laboratory Organization). HELO is an innovative design solution covering all the needs of a high throughput automated hematology platform. Flexible and efficient, HELO is the optimum answer to the constant evolution of any laboratory. The HORIBA advanced technologies embedded in the Yumizen H2500/H1500 associated with over 30 years experience in Hematology diagnosis offer the highest analytical performances. Thanks to its data, tube management, waste, blood film and digitalization management capability, HELO not only addresses a lab’s needs, but helps them to optimize TAT, floor space and reagent storage.

Related Links:
Horiba Medical 

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.